COVID-19 Science Spotlight

Download All

Keep up with the fast pace of COVID-19 research with a series of concise “Science Spotlight” commentaries and audio podcasts featuring a pair of experts discussing the most clinically relevant new COVID-19 data.

Arthur Kim, MD
person default
Christopher J. Lehmann, MD
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Josep M. Llibre, MD, PhD
Vikramjit Mukherjee, MD
person default
Gregory Olson, MD
Paul E. Sax, MD
Renslow Sherer, MD


Here are my thoughts on how developing data may help you assess immunocompromised patients’ risk of severe COVID-19 illness.

person default Christopher J. Lehmann, MD person default Gregory Olson, MD Renslow Sherer, MD Released: June 10, 2021

Navigating what is currently known about responsiveness to COVID-19 vaccines and the potential for SARS-CoV-2 variants in immunocompromised patients.

person default Christopher J. Lehmann, MD person default Gregory Olson, MD Renslow Sherer, MD Released: June 28, 2021

Neutralizing antibodies are an attractive strategy for prevention and treatment of COVID-19, particularly for unvaccinated persons and others at high risk of infection. Here’s my take on 2 exciting new studies in this field.

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: July 7, 2021

My take on the potential utility of casirivimab plus imdevimab for hospitalized patients with COVID-19 who have higher viral burden and delayed antibody responses.

Arthur Kim, MD Released: August 3, 2021

In 2020, New York City was an epicenter of the COVID-19 pandemic, and race-related disparities in patients with COVID-19 presenting to our hospital were evident. Here’s my take on 4 new analyses showing that increased risk of COVID-19 illness and poorer outcomes reflect the preexisting, deep socioeconomic inequities that affect health and access to healthcare.

Vikramjit Mukherjee, MD Released: August 4, 2021

In this commentary, I review recent studies assessing the potential role for TDF in limiting SARS-CoV-2 replication.

Josep M. Llibre, MD, PhD Released: August 16, 2021

What if one in 4 COVID-19 deaths during a surge could be avoided? My take on important new data showing that COVID-19 caseload surges adversely affect COVID-19 mortality rates.

Vikramjit Mukherjee, MD Released: September 3, 2021

Do we already have an FDA-approved, safe, and inexpensive drug that could benefit patients with COVID-19? Take a look at these promising studies of a repurposed drug—fluvoxamine—for COVID-19.

Paul E. Sax, MD Released: September 21, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings